Metropolis Healthcare Ltd: Intrinsic Value & Share Price Analysis

Last Updated: December 31, 2025, 7:48 pm

All Competitor Stocks of Metropolis Healthcare Ltd

Last Updated: December 29, 2025, 11:34 pm

Below is a detailed analysis of the quarterly data for Metropolis Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Sales, as of Sep 2025, the value is 429.00 Cr.. The value appears strong and on an upward trend. It has increased from 386.00 Cr. (Jun 2025) to 429.00 Cr., marking an increase of 43.00 Cr..
• For Expenses, as of Sep 2025, the value is 321.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 296.00 Cr. (Jun 2025) to 321.00 Cr., marking an increase of 25.00 Cr..
• For Operating Profit, as of Sep 2025, the value is 108.00 Cr.. The value appears strong and on an upward trend. It has increased from 90.00 Cr. (Jun 2025) to 108.00 Cr., marking an increase of 18.00 Cr..
• For OPM %, as of Sep 2025, the value is 25.00%. The value appears strong and on an upward trend. It has increased from 23.00% (Jun 2025) to 25.00%, marking an increase of 2.00%.
• For Other Income, as of Sep 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Jun 2025) to 1.00 Cr., marking a decrease of 7.00 Cr..
• For Interest, as of Sep 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Jun 2025) to 6.00 Cr., marking an increase of 1.00 Cr..
• For Depreciation, as of Sep 2025, the value is 32.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 31.00 Cr. (Jun 2025) to 32.00 Cr., marking an increase of 1.00 Cr..
• For Profit before tax, as of Sep 2025, the value is 71.00 Cr.. The value appears strong and on an upward trend. It has increased from 61.00 Cr. (Jun 2025) to 71.00 Cr., marking an increase of 10.00 Cr..
• For Tax %, as of Sep 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 26.00%.
• For Net Profit, as of Sep 2025, the value is 53.00 Cr.. The value appears strong and on an upward trend. It has increased from 45.00 Cr. (Jun 2025) to 53.00 Cr., marking an increase of 8.00 Cr..
• For EPS in Rs, as of Sep 2025, the value is 10.17. The value appears strong and on an upward trend. It has increased from 8.70 (Jun 2025) to 10.17, marking an increase of 1.47.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Last Updated: December 15, 2025, 4:59 am

Last Updated: Unknown

Last Updated: December 10, 2025, 3:05 am

Below is a detailed analysis of the balance sheet data for Metropolis Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
• For Reserves, as of Sep 2025, the value is 1,422.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,321.00 Cr. (Mar 2025) to 1,422.00 Cr., marking an increase of 101.00 Cr..
• For Borrowings, as of Sep 2025, the value is 201.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 204.00 Cr. (Mar 2025) to 201.00 Cr., marking a decrease of 3.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 359.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 324.00 Cr. (Mar 2025) to 359.00 Cr., marking an increase of 35.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 1,993.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,859.00 Cr. (Mar 2025) to 1,993.00 Cr., marking an increase of 134.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 1,573.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,447.00 Cr. (Mar 2025) to 1,573.00 Cr., marking an increase of 126.00 Cr..
• For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
• For Investments, as of Sep 2025, the value is 21.00 Cr.. The value appears to be declining and may need further review. It has decreased from 71.00 Cr. (Mar 2025) to 21.00 Cr., marking a decrease of 50.00 Cr..
• For Other Assets, as of Sep 2025, the value is 399.00 Cr.. The value appears strong and on an upward trend. It has increased from 341.00 Cr. (Mar 2025) to 399.00 Cr., marking an increase of 58.00 Cr..
• For Total Assets, as of Sep 2025, the value is 1,993.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,859.00 Cr. (Mar 2025) to 1,993.00 Cr., marking an increase of 134.00 Cr..

Notably, the Reserves (1,422.00 Cr.) exceed the Borrowings (201.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

After reviewing the key financial ratios for Metropolis Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 28.29. This value is within the healthy range. It has increased from 24.95 (Mar 24) to 28.29, marking an increase of 3.34.
• For Diluted EPS (Rs.), as of Mar 25, the value is 28.15. This value is within the healthy range. It has increased from 24.87 (Mar 24) to 28.15, marking an increase of 3.28.
• For Cash EPS (Rs.), as of Mar 25, the value is 49.07. This value is within the healthy range. It has increased from 43.52 (Mar 24) to 49.07, marking an increase of 5.55.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 256.94. It has increased from 213.98 (Mar 24) to 256.94, marking an increase of 42.96.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 256.94. It has increased from 213.98 (Mar 24) to 256.94, marking an increase of 42.96.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 256.99. It has increased from 235.76 (Mar 24) to 256.99, marking an increase of 21.23.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 61.41. This value is within the healthy range. It has increased from 56.94 (Mar 24) to 61.41, marking an increase of 4.47.
• For PBIT / Share (Rs.), as of Mar 25, the value is 40.43. This value is within the healthy range. It has increased from 38.50 (Mar 24) to 40.43, marking an increase of 1.93.
• For PBT / Share (Rs.), as of Mar 25, the value is 36.84. This value is within the healthy range. It has increased from 34.10 (Mar 24) to 36.84, marking an increase of 2.74.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 28.09. This value is within the healthy range. It has increased from 25.08 (Mar 24) to 28.09, marking an increase of 3.01.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 27.99. This value is within the healthy range. It has increased from 24.95 (Mar 24) to 27.99, marking an increase of 3.04.
• For PBDIT Margin (%), as of Mar 25, the value is 23.89. This value is within the healthy range. It has decreased from 24.15 (Mar 24) to 23.89, marking a decrease of 0.26.
• For PBIT Margin (%), as of Mar 25, the value is 15.73. This value is within the healthy range. It has decreased from 16.33 (Mar 24) to 15.73, marking a decrease of 0.60.
• For PBT Margin (%), as of Mar 25, the value is 14.33. This value is within the healthy range. It has decreased from 14.46 (Mar 24) to 14.33, marking a decrease of 0.13.
• For Net Profit Margin (%), as of Mar 25, the value is 10.93. This value exceeds the healthy maximum of 10. It has increased from 10.63 (Mar 24) to 10.93, marking an increase of 0.30.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.89. This value is within the healthy range. It has increased from 10.58 (Mar 24) to 10.89, marking an increase of 0.31.
• For Return on Networth / Equity (%), as of Mar 25, the value is 10.89. This value is below the healthy minimum of 15. It has decreased from 11.66 (Mar 24) to 10.89, marking a decrease of 0.77.
• For Return on Capital Employeed (%), as of Mar 25, the value is 13.31. This value is within the healthy range. It has decreased from 15.06 (Mar 24) to 13.31, marking a decrease of 1.75.
• For Return On Assets (%), as of Mar 25, the value is 7.76. This value is within the healthy range. It has decreased from 8.21 (Mar 24) to 7.76, marking a decrease of 0.45.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.77. It has decreased from 0.79 (Mar 24) to 0.77, marking a decrease of 0.02.
• For Current Ratio (X), as of Mar 25, the value is 1.18. This value is below the healthy minimum of 1.5. It has decreased from 1.28 (Mar 24) to 1.18, marking a decrease of 0.10.
• For Quick Ratio (X), as of Mar 25, the value is 1.01. This value is within the healthy range. It has decreased from 1.13 (Mar 24) to 1.01, marking a decrease of 0.12.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 30.77. This value exceeds the healthy maximum of 8. It has increased from 29.00 (Mar 24) to 30.77, marking an increase of 1.77.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 16.03 (Mar 24) to 0.00, marking a decrease of 16.03.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 9.21 (Mar 24) to 0.00, marking a decrease of 9.21.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 83.97 (Mar 24) to 0.00, marking a decrease of 83.97.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 90.79 (Mar 24) to 0.00, marking a decrease of 90.79.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 17.13. This value is within the healthy range. It has increased from 12.94 (Mar 24) to 17.13, marking an increase of 4.19.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.83. This value is within the healthy range. It has increased from 6.70 (Mar 24) to 8.83, marking an increase of 2.13.
• For Enterprise Value (Cr.), as of Mar 25, the value is 8,063.19. It has decreased from 8,775.73 (Mar 24) to 8,063.19, marking a decrease of 712.54.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 6.06. This value exceeds the healthy maximum of 3. It has decreased from 7.27 (Mar 24) to 6.06, marking a decrease of 1.21.
• For EV / EBITDA (X), as of Mar 25, the value is 25.35. This value exceeds the healthy maximum of 15. It has decreased from 30.09 (Mar 24) to 25.35, marking a decrease of 4.74.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 6.08. This value exceeds the healthy maximum of 3. It has decreased from 7.32 (Mar 24) to 6.08, marking a decrease of 1.24.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 83.96 (Mar 24) to 0.00, marking a decrease of 83.96.
• For Price / BV (X), as of Mar 25, the value is 6.08. This value exceeds the healthy maximum of 3. It has decreased from 8.07 (Mar 24) to 6.08, marking a decrease of 1.99.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 6.08. This value exceeds the healthy maximum of 3. It has decreased from 7.32 (Mar 24) to 6.08, marking a decrease of 1.24.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

About the Company - Qualitative Analysis